CY1122382T1 - Φαρμακοτεχνικες μορφες απιξαμπανης - Google Patents

Φαρμακοτεχνικες μορφες απιξαμπανης

Info

Publication number
CY1122382T1
CY1122382T1 CY20191101226T CY191101226T CY1122382T1 CY 1122382 T1 CY1122382 T1 CY 1122382T1 CY 20191101226 T CY20191101226 T CY 20191101226T CY 191101226 T CY191101226 T CY 191101226T CY 1122382 T1 CY1122382 T1 CY 1122382T1
Authority
CY
Cyprus
Prior art keywords
apxampan
pharmaceutical forms
prophylaxis
compositions
equivalent
Prior art date
Application number
CY20191101226T
Other languages
English (en)
Inventor
Jatin Patel
Charles Frost
Jingpin Jia
Chandra Vema-Varapu
Original Assignee
Bristol-Myers Squibb Holdings Ireland Unlimited Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43901603&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1122382(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Holdings Ireland Unlimited Company filed Critical Bristol-Myers Squibb Holdings Ireland Unlimited Company
Publication of CY1122382T1 publication Critical patent/CY1122382T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Συνθέσεις που περιλαμβάνουν σωματίδια κρυσταλλικής απιξαμπάνης που έχουν ένα D90 ισοδύναμο με ή λιγότερο από 89 μm, και μία φαρμακευτικώς αποδεκτή ουσία-φορέας, είναι ουσιαστικώς βιοϊσοδύναμες και μπορούν να χρησιμοποιηθούν για την αγωγή και/ή προφύλαξη θρομβοεμβολικών διαταραχών.
CY20191101226T 2010-02-25 2019-11-21 Φαρμακοτεχνικες μορφες απιξαμπανης CY1122382T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30805610P 2010-02-25 2010-02-25
EP11707284.3A EP2538925B1 (en) 2010-02-25 2011-02-24 Apixaban formulations
EP15190823.3A EP3017811B1 (en) 2010-02-25 2011-02-24 Apixaban formulations
PCT/US2011/025994 WO2011106478A2 (en) 2010-02-25 2011-02-24 Apixaban formulations

Publications (1)

Publication Number Publication Date
CY1122382T1 true CY1122382T1 (el) 2021-01-27

Family

ID=43901603

Family Applications (5)

Application Number Title Priority Date Filing Date
CY20161100194T CY1117434T1 (el) 2010-02-25 2016-03-07 Φαρμακευτικες μορφες απιξαμπανης
CY20191100249T CY1121597T1 (el) 2010-02-25 2019-02-28 Φαρμακοτεχνικες μορφες απιξαμπανης
CY20191101226T CY1122382T1 (el) 2010-02-25 2019-11-21 Φαρμακοτεχνικες μορφες απιξαμπανης
CY20191101231T CY1122384T1 (el) 2010-02-25 2019-11-22 Φαρμακοτεχνικες μορφες απιξαμπανης
CY20201100074T CY1122529T1 (el) 2010-02-25 2020-01-28 Φαρμακοτεχνικες μορφες απιξαμπανης

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CY20161100194T CY1117434T1 (el) 2010-02-25 2016-03-07 Φαρμακευτικες μορφες απιξαμπανης
CY20191100249T CY1121597T1 (el) 2010-02-25 2019-02-28 Φαρμακοτεχνικες μορφες απιξαμπανης

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY20191101231T CY1122384T1 (el) 2010-02-25 2019-11-22 Φαρμακοτεχνικες μορφες απιξαμπανης
CY20201100074T CY1122529T1 (el) 2010-02-25 2020-01-28 Φαρμακοτεχνικες μορφες απιξαμπανης

Country Status (31)

Country Link
US (5) US9326945B2 (el)
EP (7) EP3246021B1 (el)
JP (4) JP5846647B2 (el)
KR (4) KR20210124532A (el)
CN (3) CN109602713A (el)
AU (1) AU2011220775B2 (el)
BR (1) BR112012021337A8 (el)
CA (1) CA2791171C (el)
CO (1) CO6640207A2 (el)
CY (5) CY1117434T1 (el)
DK (5) DK3246021T3 (el)
ES (5) ES2758031T3 (el)
HK (5) HK1224216A1 (el)
HR (5) HRP20160179T1 (el)
HU (4) HUE047139T2 (el)
IL (3) IL309564A (el)
IN (1) IN2012DN06587A (el)
LT (4) LT3257500T (el)
MX (3) MX353145B (el)
NZ (1) NZ601738A (el)
PE (3) PE20160042A1 (el)
PL (5) PL3246021T3 (el)
PT (5) PT2538925E (el)
RS (5) RS54559B1 (el)
RU (1) RU2685724C2 (el)
SG (2) SG10201501349VA (el)
SI (5) SI3017811T1 (el)
SM (1) SMT201600049B (el)
TR (1) TR201903195T4 (el)
WO (1) WO2011106478A2 (el)
ZA (1) ZA201205807B (el)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3017811T1 (sl) * 2010-02-25 2019-04-30 Bristol-Myers Squibb Holdings Ireland Unlimited Company Formulacije apiksabana
WO2013164839A2 (en) * 2012-03-06 2013-11-07 Cadila Healthcare Limited Amorphous form of apixaban, process of preparation and compositions thereof
CA2873949A1 (en) * 2012-05-24 2013-11-28 Ratiopharm Gmbh Dosage forms comprising apixaban and matrix former
AU2013323435C1 (en) * 2012-09-26 2018-04-12 Bristol-Myers Squibb Holdings Ireland Unlimited Company Apixaban liquid formulations
CN102908324A (zh) * 2012-10-31 2013-02-06 南京正科制药有限公司 一种阿哌沙班片
EP2752414A1 (en) 2013-01-04 2014-07-09 Sandoz AG Crystalline form of apixaban
CZ2013305A3 (cs) 2013-04-23 2014-11-05 Zentiva, K.S. Nové krystalické formy APIXABANU a způsob jejich přípravy
US20160113912A1 (en) * 2013-06-18 2016-04-28 Cadila Healthcare Limited An improved process for the preparation of apixaban and intermediates thereof
EP2907507A1 (en) * 2014-02-17 2015-08-19 Sandoz Ag Pharmaceutical composition comprising apixaban
CN103830199A (zh) * 2014-03-24 2014-06-04 重庆东得医药科技有限公司 含阿哌沙班的药用制剂及其制备方法
CN104316637B (zh) * 2014-10-30 2016-08-17 江苏宝众宝达药业有限公司 高效液相色谱法测定阿哌沙班清洗残留量
US9603846B2 (en) 2014-11-25 2017-03-28 Cadila Healthcare Limited Process for the preparation of apixaban
BR112017016393A2 (pt) * 2015-05-08 2018-03-27 Wockhardt Limited composições farmacêuticas estáveis compreendendo agente antibacteriano
WO2017088841A1 (en) 2015-11-26 2017-06-01 Zentiva, K.S. Preparation of a drug form containing amorphous apixaban
CN106913528A (zh) * 2015-12-25 2017-07-04 中美华世通生物医药科技（武汉）有限公司 阿哌沙班微丸及其制备方法
US10537524B2 (en) * 2016-01-12 2020-01-21 North & South Brother Pharmacy Investment Company Limited Apixaban solid composition and preparation method thereof
EP3195860A1 (de) * 2016-01-22 2017-07-26 STADA Arzneimittel AG Verfahren zur herstellung eines apixaban-granulates
WO2017163170A1 (en) * 2016-03-21 2017-09-28 Sun Pharmaceutical Industries Limited Pharmaceutical composition comprising apixaban
WO2017182908A1 (en) * 2016-04-18 2017-10-26 Emcure Pharmaceuticals Limited Pharmaceutical compositions of apixaban
EP3243505A1 (en) 2016-05-13 2017-11-15 Zaklady Farmaceutyczne Polpharma SA A pharmaceutical composition comprising amorphous apixaban
CN106822006B (zh) * 2016-06-08 2020-08-28 北京普德康利医药科技发展有限公司 一种阿哌沙班片及其制备方法
WO2017221209A1 (en) 2016-06-23 2017-12-28 Lupin Limited Pharmaceutical formulations of apixaban
JP7090599B2 (ja) * 2016-09-24 2022-06-24 山東亨利醫藥科技有限責任公司 ミネラルコルチコイド受容体拮抗薬を含む医薬組成物及びその使用
CN106420651B (zh) * 2016-09-28 2019-03-08 乐普药业股份有限公司 一种阿哌沙班片的制备方法
EP3582777A4 (en) 2017-02-17 2020-12-23 Unichem Laboratories Ltd PHARMACEUTICAL COMPOSITION OF APIXABAN
KR102470151B1 (ko) 2017-11-27 2022-11-25 미쯔비시 케미컬 주식회사 고무 함유 그래프트 중합체, 고무 함유 그래프트 중합체 함유 수지 조성물 및 그의 성형체
KR20190075566A (ko) 2017-12-21 2019-07-01 전자부품연구원 다중 센서를 활용한 용변 습관 모니터링 시스템 및 방법
TR201722523A2 (tr) 2017-12-28 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Api̇ksaban i̇çeren kati oral farmasöti̇k kompozi̇syonlar
CN108236604A (zh) * 2018-02-07 2018-07-03 中国药科大学 阿哌沙班柔性脂质体
HRP20240529T1 (hr) 2018-04-16 2024-07-05 Bristol-Myers Squibb Company Formulacije apiksabana
KR20190130411A (ko) * 2018-05-14 2019-11-22 신일제약주식회사 아픽사반 약제학적 제제 및 그의 제조방법
AU2019322287A1 (en) 2018-08-14 2021-03-11 Jiangsu Hengrui Medicine Co., Ltd. Injectable pharmaceutical composition and preparation method therefor
EP3666773A1 (en) 2018-12-11 2020-06-17 KRKA, D.D., Novo Mesto Process for preparing apixaban
EP3669866A1 (en) 2018-12-19 2020-06-24 KRKA, d.d., Novo mesto Pharmaceutical composition comprising apixaban
CN111377915B (zh) * 2018-12-30 2023-10-24 鲁南制药集团股份有限公司 一种吡唑并-吡啶酮化合物晶型d
CN109464415B (zh) * 2019-01-09 2021-08-17 常州恒邦药业有限公司 阿哌沙班药物组合物及其制备方法
CN111214442B (zh) * 2020-02-13 2021-12-10 山东百诺医药股份有限公司 一种阿哌沙班共微粉化物
CN111494326A (zh) * 2020-04-11 2020-08-07 南京正大天晴制药有限公司 一种阿哌沙班片及其制备方法
WO2022115052A1 (en) 2020-11-27 2022-06-02 Santa Farma Ilac Sanayii A.S. Improved wet granulation processes for apixaban comprising formulations
EP4251271A4 (en) 2020-11-27 2024-07-31 Santa Farma Ilac Sanayii A S DIRECT COMPRESSION PROCESS FOR NON-MICRONIZED APIXABAN FORMULATIONS
TR202100250A2 (tr) 2021-01-08 2022-07-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Api̇ksaban i̇çeren fi̇lm kapli tablet
WO2022150030A2 (en) 2021-01-08 2022-07-14 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A film coated tablet of apixaban
GB202102575D0 (en) 2021-02-23 2021-04-07 Teva Pharmaceutical Industries Ltd Fixed-dose pharmaceutical compositions
CN117440807A (zh) * 2021-06-08 2024-01-23 泰合生技药品股份有限公司 阿哌沙班膜产品及其用途
WO2023072967A1 (en) 2021-10-27 2023-05-04 Pharma-Data S.A. Apixaban suspension and preparation method

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150366A (en) 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
SI1140941T1 (en) 1998-12-23 2005-04-30 Bristol-Myers Squibb Pharma Company Nitrogen containing heterobicycles as factor xa inhibitors
PL204263B1 (pl) 2001-09-21 2009-12-31 Bristol Myers Squibb Co Pochodna 1H-pirazolo[3,4-c]pirydyny i jej zastosowanie oraz kompozycja farmaceutyczna i jej zastosowanie
TWI331526B (en) 2001-09-21 2010-10-11 Bristol Myers Squibb Pharma Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
US20070025991A1 (en) * 2003-03-19 2007-02-01 Charalabos Pothoulakis Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation
US20050059719A1 (en) * 2003-09-16 2005-03-17 Badawy Sherif Ibrahim Farag Solid dosage formulation containing a Factor Xa inhibitor and method
DE10355461A1 (de) * 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
US7434502B2 (en) 2004-07-21 2008-10-14 Husqvarna Outdoor Products Inc. Bar knob with cam-operated locking mechanism
US20060016084A1 (en) * 2004-07-24 2006-01-26 Ching-Lin Liao Laser-Based datum instrument
US7396932B2 (en) 2004-09-28 2008-07-08 Bristol-Myers Squibb Company Process for preparing 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
US20060160841A1 (en) * 2005-01-19 2006-07-20 Chenkou Wei Crystallization via high-shear transformation
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
US20070191306A1 (en) 2005-08-17 2007-08-16 Bristol-Myers Squibb Company FACTOR Xa INHIBITOR FORMULATION AND METHOD
EP1951197A4 (en) 2005-11-10 2011-12-21 Alphapharm Pty Ltd METHOD OF CHECKING THE PARTICLE SIZE
US20070259913A1 (en) 2006-05-04 2007-11-08 David Deitchman Prophylaxis of thromboembolic events in cancer patients
US20090285887A1 (en) 2006-09-12 2009-11-19 Omar Abdelfattah Abu-Baker Pharmaceutical Composition Comprising A Plurality of Mini-Tablets Comprising A Factor XA Inhibitor
FI20080351A0 (fi) 2008-05-09 2008-05-09 Atacama Labs Oy Prosessi matalan lääkepitoisuuden tabletin valmistamiseksi
US20080279845A1 (en) * 2007-05-02 2008-11-13 Portola Pharmaceuticals, Inc. Combination therapy with a compound acting as a platelet adp receptor inhibitor
US8865692B2 (en) * 2007-11-13 2014-10-21 Meritage Pharma, Inc Compositions for the treatment of gastrointestinal inflammation
CA2723409C (en) * 2008-05-09 2016-11-08 Atacama Labs Oy Method and apparatus for dry granulation
JP2011527668A (ja) 2008-07-11 2011-11-04 ビーエーエスエフ ソシエタス・ヨーロピア 形態改質剤としての両親媒性タンパク質
US20100018486A1 (en) * 2008-07-22 2010-01-28 Hung-Tao Liu Cathode energy fuel-saving device
EP3563842A1 (en) * 2009-04-29 2019-11-06 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
DK2442791T3 (da) 2009-06-16 2020-03-02 Pfizer Former til dosering af apixaban
SI3017811T1 (sl) 2010-02-25 2019-04-30 Bristol-Myers Squibb Holdings Ireland Unlimited Company Formulacije apiksabana
JP6092629B2 (ja) * 2010-03-10 2017-03-08 ルピン・リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ リファキシミン使用準備済懸濁液

Also Published As

Publication number Publication date
IL309564A (en) 2024-02-01
RS59576B1 (sr) 2019-12-31
JP6192078B2 (ja) 2017-09-06
CA2791171C (en) 2017-08-29
HK1243946A1 (zh) 2018-07-27
JP6033945B2 (ja) 2016-11-30
EP3251660A1 (en) 2017-12-06
HRP20160179T1 (hr) 2016-04-08
JP2017039768A (ja) 2017-02-23
JP2017226679A (ja) 2017-12-28
CY1117434T1 (el) 2017-04-26
EP3257500A1 (en) 2017-12-20
SG182750A1 (en) 2012-08-30
RU2012140690A (ru) 2014-03-27
PT3251660T (pt) 2019-12-02
KR101796300B1 (ko) 2017-11-10
WO2011106478A2 (en) 2011-09-01
NZ601738A (en) 2014-02-28
WO2011106478A3 (en) 2012-04-12
IL221064A0 (en) 2012-09-24
US9326945B2 (en) 2016-05-03
PT3257500T (pt) 2019-11-26
PE20210468A1 (es) 2021-03-08
SI3246021T1 (sl) 2020-03-31
HUE043932T2 (hu) 2019-09-30
JP6577980B2 (ja) 2019-09-18
EP2538925A2 (en) 2013-01-02
CN109602716A (zh) 2019-04-12
EP3251660B1 (en) 2019-10-16
DK3017811T3 (en) 2019-04-01
US20170202825A1 (en) 2017-07-20
PE20160042A1 (es) 2016-01-28
EP3017811A1 (en) 2016-05-11
RS58699B1 (sr) 2019-06-28
US20160243101A1 (en) 2016-08-25
MX2012009244A (es) 2012-08-23
ES2757603T3 (es) 2020-04-29
US20130045245A1 (en) 2013-02-21
PL3246021T3 (pl) 2020-04-30
EP2538925B1 (en) 2015-12-16
EP3017811B1 (en) 2018-12-05
JP2013521226A (ja) 2013-06-10
CY1122384T1 (el) 2021-01-27
HRP20192064T1 (hr) 2020-02-21
HK1180248A1 (zh) 2013-10-18
BR112012021337A2 (pt) 2016-10-25
BR112012021337A8 (pt) 2016-11-29
DK3257500T3 (da) 2019-11-25
SI3017811T1 (sl) 2019-04-30
HK1243947B (zh) 2020-06-19
RS59810B1 (sr) 2020-02-28
PT2538925E (pt) 2016-03-18
CO6640207A2 (es) 2013-03-22
MX364938B (es) 2019-05-15
ES2714363T3 (es) 2019-05-28
SI3251660T1 (sl) 2019-12-31
EP3257500B1 (en) 2019-10-16
HUE047139T2 (hu) 2020-04-28
LT3257500T (lt) 2019-12-10
ZA201205807B (en) 2016-01-27
DK3246021T3 (da) 2020-02-03
SI2538925T1 (sl) 2016-04-29
MX353145B (es) 2017-12-20
PL3251660T3 (pl) 2020-02-28
PE20130378A1 (es) 2013-03-30
SI3257500T1 (sl) 2019-12-31
EP3246021A1 (en) 2017-11-22
US20200375968A1 (en) 2020-12-03
IL251991A0 (en) 2017-06-29
HK1224216A1 (zh) 2017-08-18
PT3017811T (pt) 2019-03-21
US20170202824A1 (en) 2017-07-20
KR20230149861A (ko) 2023-10-27
LT3017811T (lt) 2019-02-25
CY1122529T1 (el) 2021-01-27
DK3251660T3 (da) 2019-11-25
ES2562279T3 (es) 2016-03-03
EP3246021B1 (en) 2019-11-13
LT3246021T (lt) 2020-02-10
CY1121597T1 (el) 2020-05-29
HRP20192069T1 (hr) 2020-02-07
HUE027168T2 (en) 2016-10-28
PT3246021T (pt) 2020-02-21
RS54559B1 (en) 2016-06-30
LT3251660T (lt) 2019-12-10
SG10201501349VA (en) 2015-04-29
ES2767848T3 (es) 2020-06-18
KR20170126016A (ko) 2017-11-15
HK1243945B (zh) 2020-06-19
TR201903195T4 (tr) 2019-03-21
AU2011220775A1 (en) 2012-09-13
IN2012DN06587A (el) 2015-10-23
HRP20190430T8 (hr) 2019-06-14
KR20210124532A (ko) 2021-10-14
EP3643301A1 (en) 2020-04-29
RU2685724C2 (ru) 2019-04-23
KR20130009753A (ko) 2013-01-23
PL3257500T3 (pl) 2020-03-31
HRP20200046T1 (hr) 2020-03-20
JP5846647B2 (ja) 2016-01-20
JP2016065086A (ja) 2016-04-28
SMT201600049B (it) 2016-04-29
PL3017811T3 (pl) 2019-06-28
ES2758031T8 (es) 2020-08-05
ES2758031T3 (es) 2020-05-04
HRP20190430T1 (hr) 2019-05-17
CN109602713A (zh) 2019-04-12
HUE047140T2 (hu) 2020-04-28
AU2011220775B2 (en) 2015-09-24
CA2791171A1 (en) 2011-09-01
DK2538925T3 (en) 2016-03-14
CN102770126A (zh) 2012-11-07
RS59593B1 (sr) 2020-01-31
EP3662899A1 (en) 2020-06-10
PL2538925T3 (pl) 2016-06-30

Similar Documents

Publication Publication Date Title
CY1122384T1 (el) Φαρμακοτεχνικες μορφες απιξαμπανης
CY1123637T1 (el) Αναστολεις μεθυλοτρανσφερασης αργινινης και χρησεις αυτων
CY1122718T1 (el) Σκευασμα συνδυασμου δυο αντι-ιικων ενωσεων
CL2012003421A1 (es) Compuestos derivados de 3-amino-n-(4-carbamoilpiridin-3-il)(aril/heteroaril)-2-carboxamida; procedimiento de preparacion; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad del snc, oncologica, entre otras. pct fase nacional
CY1122566T1 (el) Παραγωγο 6,7,8,9-tetpaϋδpo-3h-πυραζολo[4,3-f] ισοκινολινης χρησιμο στη θεραπευτικη αντιμετωπιση του καρκινου
PH12015502004A1 (en) Tetracyclic bromodomain inhibitors
CL2012002497A1 (es) Compuestos derivados de imidazopirimidina,sustituidos, inhibidores de la pde10a; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o prevencion de trastornos psicoticos, esquizofrenia, enfermedad de parkinson, esclerosis multiple, entre otras.
WO2014153100A3 (en) Arginine methyltransferase inhibitors and uses thereof
EA201071291A2 (ru) Nmda рецепторные антагонисты для лечения нейропсихиатрических расстройств
BR112015020139A2 (pt) compostos terapêuticos e usos dos mesmos
CY1119785T1 (el) 2,4,6-τριφθορο-ν-[6-(1-μεθυλο-πιπεριδινο-4-καρβονυλο)-πυριδιν-2-υλο]-βενζαμιδιο για την αντιμετωπιση ημικρανιας μεσω της στοματικης ή της ενδοφλεβιας οδου
CU20120002A7 (es) DERIVADOS DE 1-(5,6-DIHIDROIMIDAZO(1,2-a)PIRAZIN-7(8H)-IL )ETANONA
UY35275A (es) Derivados de aminopirazina
CL2015001374A1 (es) Compuestos derivados de 2-(metilamino)-n-(2-oxo-2,3,4,5-tetrahidro-1h-1,5-benzodiazepin-3il)propanamida; composicion farmaceutica; y su uso en el tratamiento terapeutico o profilactico del cancer.
CL2011001405A1 (es) Procedimiento para la preparacion de n-[2-(7-metoxi-1-naftil)etil]acetamida, agometalina.
WO2014153495A9 (en) Novel stat3 inhibitors
CY1116234T1 (el) Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
CY1118570T1 (el) Νεα συνθεση αλφαιντανυλης για την αγωγη του οξεος πονου
WO2015002755A3 (en) Compounds for the treatment of malaria
CY1118132T1 (el) ΣΤΕΡΕΕΣ ΜΟΡΦΕΣ ΤΗΣ ΥΔΡΟΧΛΩΡΙΚΗΣ (1R,4R)-6'-ΦΘΟΡΟ-Ν,Ν-ΔΙΜΕΘΥΛ-4-ΦΑΙΝΥΛ-4',9'-ΔΙΥΔΡΟ-3´H-ΣΠΕΙΡΟ-[ΚΥΚΛΟΕΞΑΝΟ-1,1'-ΠΥΡΑΝΟ[3,4,b]ΙΝΔΟΛ]-4-ΑΜΙΝΗΣ
TR201000689A1 (tr) Sefprozil içeren katı dozaj formlar.
CL2011002967A1 (es) Compuestos derivados de 3-oxadiazolil-5-fenil-piperidina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamient y/o profilaxis de trastornos cardiovasculares, tromboembolicos y tumorales.
BR112014032037A2 (pt) formulações para a preparação de comprimidos de liberação imediata para uso oral contendo uma baixa dosagem de mifepristona para o tratamento de endometriose, comprimidos desse modo obtidos e seu processo de preparação
BR112014009217A2 (pt) antibacterianos à base de fenicol
IN2014KN02584A (el)